Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

Group 1 - The core viewpoint of the article is that Tongce Medical has disclosed information regarding its total number of shareholders, which exceeds 90,000 as of January 10, 2026 [2] - The company emphasizes the importance of ensuring that all investors have fair access to information, indicating that future updates on shareholder numbers will be provided in formal periodic reports [2]

Core Viewpoint - Tongce Medical (600763) shows a steady growth in revenue and net profit, indicating a stable performance in the medical services sector [2]. Group 1: Stock Performance - As of January 12, 2026, Tongce Medical's stock closed at 42.34 yuan, up by 1.61%, with a turnover rate of 2.38% and a trading volume of 106,300 lots, resulting in a transaction value of 448 million yuan [1]. - On January 12, the net inflow of main funds was 22.82 million yuan, accounting for 5.09% of the total transaction value, while retail investors saw a net outflow of 21.28 million yuan, representing 4.75% of the total transaction value [1]. Group 2: Financial Performance - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, an increase of 2.56% year-on-year, and a net profit attributable to shareholders of 514 million yuan, up by 3.16% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 842 million yuan, reflecting a year-on-year increase of 2.34%, and a net profit of 192 million yuan, which is a 2.31% increase year-on-year [2]. - The company's debt ratio stands at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, while the gross profit margin is reported at 41.69% [2]. Group 3: Analyst Ratings - In the last 90 days, seven institutions have provided ratings for Tongce Medical, with four giving a "buy" rating and three an "increase" rating [2]. - The average target price set by institutions over the past 90 days is 5.29 billion yuan [2].

来源：市场资讯 有投资者在互动平台向通策医疗提问："请问截止2026年1月10日公司的股东数是多少？" 针对上述提问，通策医疗回应称："您好，截至2026年1月10日公司股东总数为9万多。为确保所有投资 者能公平地获取信息，相关股东人数信息后续请以公司正式披露的定期报告为准，感谢您的关注。" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 ...

证券之星消息，截至2026年1月7日收盘，通策医疗(600763)报收于41.02元，下跌0.65%，换手率 1.34%，成交量5.99万手，成交额2.46亿元。 1月7日的资金流向数据方面，主力资金净流出2848.85万元，占总成交额11.56%，游资资金净流入 914.14万元，占总成交额3.71%，散户资金净流入1934.71万元，占总成交额7.85%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 通策医疗2025年三季报显示，前三季度公司主营收入22.9亿元，同比上升2.56%；归母净利润5.14亿 元，同比上升3.16%；扣非净利润5.09亿元，同比上升3.09%；其中2025年第三季度，公司单季度主营收 入8.42亿元，同比上升2.34%；单季度归母净利润1.92亿元，同比上升2.31%；单季度扣非净利润1.92亿 元，同比上升1.85%；负债率25.1%，投资收益4122.43万元，财务费用3192.82万元，毛利率41.69%。通 策医疗（600763）主营业务：医疗服务。 该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为 52.88 ...

Group 1 - The core viewpoint of the news is that Tongce Medical (600763) has shown a slight increase in stock price and has reported positive financial performance in its recent quarterly results [1][2] - As of January 6, 2026, Tongce Medical's stock closed at 41.29 yuan, with a trading volume of 79,900 hands and a total transaction amount of 329 million yuan [1] - In the recent funding flow data, the main funds experienced a net outflow of 9.82 million yuan, while retail investors saw a net inflow of 10.79 million yuan, indicating a mixed sentiment among different investor groups [1] Group 2 - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2] - The company's third-quarter results showed a single-quarter main revenue of 842 million yuan, reflecting a year-on-year increase of 2.34%, and a net profit of 192 million yuan, up 2.31% year-on-year [2] - The company has a debt ratio of 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, while maintaining a gross profit margin of 41.69% [2]

Core Viewpoint - Tongce Medical (600763) shows a positive stock performance with a closing price of 41.14 yuan, up 2.31% as of January 5, 2026, despite a net outflow of main funds [1] Group 1: Stock Performance and Trading Data - On January 5, 2026, the stock had a turnover rate of 1.75%, with a trading volume of 78,100 hands and a total transaction amount of 319 million yuan [1] - The fund flow data indicates a net outflow of 33.46 million yuan from main funds, accounting for 10.49% of the total transaction amount, while retail investors saw a net inflow of 20.98 million yuan, representing 6.58% of the total [1] Group 2: Recent Fund Flow Overview - Over the past five days, the stock experienced varying fund flows, with the following notable figures: - January 5: Main funds net outflow of 33.46 million yuan, retail net inflow of 20.98 million yuan [2] - December 31: Main funds net outflow of 6.31 million yuan, retail net inflow of 3.45 million yuan [2] - December 30: Main funds net outflow of 0.10 million yuan, retail net inflow of 13.57 million yuan [2] - December 29: Main funds net outflow of 19.18 million yuan, retail net inflow of 11.71 million yuan [2] - December 26: Main funds net outflow of 21.40 million yuan, retail net inflow of 28.34 million yuan [2] Group 3: Company Financial Metrics and Industry Comparison - Tongce Medical has a total market value of 18.40 billion yuan, ranking 9th in the medical services industry [3] - The company reported a net profit of 514 million yuan, which is an increase of 3.16% year-on-year, and a net asset of 4.70 billion yuan [3] - The company’s gross margin stands at 41.69%, significantly higher than the industry average of 36.47% [3] - The return on equity (ROE) is 11.8%, compared to the industry average of 3.46%, indicating strong profitability [3] Group 4: Analyst Ratings and Price Targets - In the last 90 days, seven institutions have rated the stock, with four buy ratings and three hold ratings [4] - The average target price set by analysts for the stock is 52.88 yuan [4]

Core Insights - The medical services sector experienced a significant increase of 4.77% on January 5, with Sanbo Brain Science leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] Medical Services Sector Performance - Sanbo Brain Science (301293) closed at 70.78, with a rise of 20.01% and a trading volume of 106,700 shares, amounting to a transaction value of 755 million [1] - Likang Life (300143) saw a closing price of 11.38, increasing by 15.18% with a trading volume of 473,200 shares, totaling 518 million [1] - Chengdu Xian Dao (688222) closed at 26.14, up 11.47%, with a trading volume of 277,100 shares, resulting in a transaction value of 704 million [1] - Other notable performers include She Nei Medical (301060) at 10.20 (+10.27%), International Medical (000516) at 4.72 (+10.02%), and Zhaoyan New Drug (603127) at 38.51 (+10.00%) [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.028 billion from institutional investors, while retail investors contributed a net inflow of 174 million [2] - Notable net inflows from institutional investors include Zhaoyan New Drug (603127) with 235 million and Sanbo Brain Science (301293) with 214 million [3] - Conversely, retail investors showed significant outflows from several stocks, including Sanbo Brain Science (301293) with a net outflow of 136 million and Likang Life (300143) with 27.9 million [3]

Core Insights - The health service industry aims to create a favorable organizational environment by providing safe, effective, convenient, and affordable basic medical and public health services to meet various health needs of residents. The demand for health-related products and services is rapidly increasing due to social progress and changes in lifestyle [1][7]. Industry Overview - The health service industry encompasses medical services, health management, health insurance, and related services, involving pharmaceuticals, medical devices, health products, and fitness products [4]. - The industry has experienced rapid growth in China, with the market size increasing from 6.37 trillion yuan in 2018 to an expected 9.55 trillion yuan by 2024, representing a compound annual growth rate of 6.98%. The "Healthy China 2030" plan projects the total market size to reach 16 trillion yuan by 2030, indicating significant growth potential [1][8]. Development History - The development of China's health service industry can be divided into four stages: 1. 1949-1990: Health check-ups were primarily hospital services focused on disease detection rather than prevention. 2. 1991-2000: Independent health check-up service institutions began to emerge in cities like Beijing. 3. 2001-2010: The introduction of Western health service concepts and rapid market demand growth led to the fast development of health service institutions. 4. 2011-present: Increased focus on medical information technology and service upgrades has improved the capabilities of health service institutions [4][5]. Relevant Policies - Recent government policies aim to optimize resource allocation, enhance preventive interventions, and improve service accessibility, which helps control the rapid growth of medical costs and reduce the disease burden on families and society. For instance, the National Health Commission issued a notice in February 2025 to address public health concerns and improve service efficiency [6]. Industry Structure and Key Companies - The operational models of health service institutions in China are diverse, including: 1. Hospital-based models leveraging brand and client resources. 2. Independent medical models with self-owned brands and facilities. 3. Health management models centered on health check-ups. 4. Comprehensive information platform models connecting online and offline services [8]. - Major companies in the health service industry include: - Meinian Health Industry Holdings Co., Ltd. - Tongce Medical Co., Ltd. - Ruici Medical Service Holdings Co., Ltd. - Ciming Health Checkup Management Group Co., Ltd. - Aikang Guobin Health Checkup Management Group Co., Ltd. [2][3][9]. Trends in Health Services - The future of health services will focus on personalized and precise care, moving from a "one-size-fits-all" approach to individualized health management based on personal data [11]. - Service delivery will become decentralized, extending beyond traditional healthcare facilities to community and home settings, enhancing accessibility and convenience [12]. - Payment models will evolve from fee-for-service to value-based care, with insurance companies and service providers collaborating to create innovative health products [13].

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Tongce Medical (600763) as of December 29, 2025, with a closing price of 40.55 yuan, reflecting a decrease of 0.93% [1] - The company reported a main revenue of 2.29 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 2.56% [2] - The net profit attributable to shareholders for the same period was 514 million yuan, up 3.16% year-on-year, while the net profit excluding non-recurring items was 509 million yuan, increasing by 3.09% [2] Group 2 - In Q3 2025, the company achieved a single-quarter main revenue of 842 million yuan, which is a 2.34% year-on-year increase [2] - The net profit attributable to shareholders for Q3 2025 was 192 million yuan, reflecting a year-on-year growth of 2.31% [2] - The company has a debt ratio of 25.1% and reported investment income of 41.22 million yuan, with financial expenses amounting to 31.93 million yuan and a gross profit margin of 41.69% [2] Group 3 - The stock experienced a net outflow of 19.18 million yuan from main funds, accounting for 11.06% of the total transaction amount, while retail investors saw a net inflow of 11.71 million yuan, representing 6.75% of the total [1] - Over the past 90 days, seven institutions have provided ratings for the stock, with four giving a buy rating and three an increase rating, while the average target price set by institutions is 5.29 billion yuan [2]